Insulet Corp(PODD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:55 PM ET (Korea 10/28 05:55)
Full metrics table
| Index | S&P 500 | P/E | 29.7 | EPS (ttm) | 5.04 | Insider Own | 0.44% | Shs Outstand | 69.3M | Perf Week | 5.04% |
| Market Cap | 10.39B | Forward P/E | 19.4 | EPS next Y | 18.68% | Insider Trans | 2.32% | Shs Float | 69.0M | Perf Month | 12.56% |
| Enterprise Value | 10.80B | PEG | 0.83 | EPS next Q | 1.59 | Inst Own | 106.09% | Short Float | 8.15% | Perf Quarter | -12.18% |
| Income | 0.38B | P/S | 3.4 | EPS this Y | 30.93% | Inst Trans | 1.79% | Short Ratio | 3.33 | Perf Half Y | -18.07% |
| Sales | 3.05B | P/B | 7.31 | EPS next 5Y | 23.3% | ROA | 11.31% | Short Interest | 5.63M | Perf YTD | -47.29% |
| Book/sh | 20.51 | P/C | 19.43 | EPS past 3/5Y | 275.33% 102.14% | ROE | 26.02% | 52W High | -57.78% ($354.88) | Perf Year | -54.01% |
| Cash/sh | 7.71 | P/FCF | 35.37 | Sales past 3/5Y | 27.54% 24.53% | ROIC | 15.96% | 52W Low | 18.54% ($126.40) | Perf 3Y | 12.29% |
| Dividend Est. | - | EV/EBITDA | 16.89 | EPS Y/Y TTM | 59.39% | Gross Margin | 72.16% | Volatility(W/M) | 3.37% 2.89% | Perf 5Y | -49.94% |
| Dividend TTM | - | EV/Sales | 3.54 | Sales Y/Y TTM | 29.41% | Oper. Margin | 16.88% | ATR (14) | 4.49 | Perf 10Y | 304.18% |
| Dividend Ex-Date | - | Quick Ratio | 1.8 | EPS Q/Q | 234.76% | Profit Margin | 12.29% | RSI (14) | 66.98 | Recom | 2.07 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.45 | Sales Q/Q | 23.51% | SMA20 | 7.72% ($139.09) | Beta | 1.08 | Target Price | $165 |
| Payout | - | Debt/Eq | 0.67 | Earnings | 2026/11/4 | SMA50 | 6.4% ($140.82) | Rel Volume | 0.56 | Prev Close | $149.26 |
| Employees | 5400 | LT Debt/Eq | 0.65 | EPS/Sales Surpr. | 13.11% 1.82% | SMA200 | -17.1% ($180.74) | Avg Volume(3M) | 1.69M | Price | $149.83 |
| IPO | 2007/5/15 | Option/Short | Yes/Yes | Trades | 17584 | Volume | 943,579 | Change | 0.38% |
This US medical device company develops and sells tubeless, disposable insulin pumps (Omnipod), a diabetes management device. Its growth is driven by recurring revenue from consumable pumps and the expanding diabetic population.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded less than usual. That is 56% of its average volume.
Next earnings report: November 4
7 days to go.
PODD makes money exceptionally well
Of every $100 in sales, $16.88 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +30.9% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,689. Peers typically go for $1,594. Compared with its own 5-year average, it is 67% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -49.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 106.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #15 of 142 in the industry
Based on market cap of $10B.
GMED#13 Globus Medical Inc $11B PER 20.7 
GKOS#14 Glaukos Corp $11B PER - PODD#15 Insulet Corp $10B PER 29.7 
BIO#16 Bio-Rad Laboratories Inc $10B PER 46.2 
TXG#17 10x Genomics Inc $10B PER - 
FAQ
What kind of company is PODD?
PODD belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of PODD?
The market cap of PODD is approximately $10.4B, ranking 905 within its sector.
What is the P/E ratio of PODD?
PODD has a P/E ratio of approximately 29.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PODD?
PODD has recorded a 52-week high of $354.88 and a low of $126.40.
